The effectiveness of lysostaphin therapy for experimental coagulase-negative Staphylococcus endophthalmitis

Current Eye Research
Clare C McCormickRichard J O'Callaghan

Abstract

To quantitatively determine the effectiveness of lysostaphin therapy for experimental endophthalmitis mediated by coagulase-negative Staphylococcus species, the leading cause of postsurgical endophthalmitis. Minimal inhibitory concentrations (MIC) of lysostaphin were determined for 54 isolates representing the following species: S. epidermidis, S. warneri, S. haemolyticus, S. cohnii, S. simulans, and S. capitis. The effectiveness of lysostaphin therapy was tested in an experimental model of endophthalmitis by intravitreally injecting log phase bacteria (100 colony-forming units; cfu) into rabbit eyes (n = 3 eyes per group). At 8 hr postinfection (PI), lysostaphin (250 microg) was injected intravitreally, and the number of cfu/ml of vitreous was determined at 24 hr PI. Average MIC for S. epidermidis was 0.7 microg/ml for 90% of the 33 strains tested. Six methicillin-resistant strains of S. epidermidis (MRSE) had an average MIC of 0.74 micro g/ml. All other species had MIC values of =1.1 microg/ml, except for one strain of S. capitis (MIC = 15.6 microg/ml) and one S. haemolyticus (MIC = 1.41 microg/ml). At 24 hr PI, all untreated eyes had between 5.7 and 8.08 log cfu/ml vitreous humor. Treatment with lysostaphin significantly red...Continue Reading

References

Jan 1, 1978·International Urology and Nephrology·M Reuter, H J Reuter
Apr 1, 1977·The British Journal of Ophthalmology·G A PeymanD R May
Feb 1, 1975·Journal of Clinical Microbiology·R E PerkinsH M Leibowitz
Oct 1, 1975·International Journal of Radiation Oncology, Biology, Physics·W G ConnorN Sheeley
Jul 1, 1992·The British Journal of Ophthalmology·C J HeavenD L Boase
Nov 1, 1988·Archives of Ophthalmology·D F Goodman, J D Gottsch
Apr 1, 1986·Ophthalmology·W T DriebeW W Culbertson
Mar 15, 1986·American Journal of Ophthalmology·A B FleischerR P Burns
Dec 1, 1985·The British Journal of Ophthalmology·D D BodéR K Forster
Dec 1, 1983·Annals of Internal Medicine·F D Lowy, S M Hammer
Apr 1, 1982·Archives of Ophthalmology·J P FisherR K Forster
Sep 1, 1982·American Journal of Ophthalmology·G HopenJ Lipkowitz
Apr 15, 1993·American Journal of Ophthalmology·M Maffett, D M O'Day
May 20, 1998·Optometry and Vision Science : Official Publication of the American Academy of Optometry·E C LeitchM D Willcox
Mar 12, 1999·Annual Review of Medicine·J Huebner, D A Goldmann
Sep 15, 1999·Ophthalmology·R Axer-SiegelD Weinberger
Oct 24, 2001·The British Journal of Ophthalmology·I M GanJ C van Meurs
Jan 10, 2002·Clinical Microbiology Reviews·Michelle C CalleganMichael S Gilmore
Aug 21, 2003·The British Journal of Ophthalmology·T WongC N J McGhee
Mar 1, 1964·Proceedings of the National Academy of Sciences of the United States of America·C A SCHINDLER, V T SCHUHARDT
Oct 25, 2003·Antimicrobial Agents and Chemotherapy·Julie A WuJohn F Kokai-Kun
Jan 1, 2004·American Journal of Ophthalmology·Matthew S BenzDarlene Miller

❮ Previous
Next ❯

Citations

Oct 19, 2012·Applied Microbiology and Biotechnology·Piotr SzwedaSlawomir Milewski
Mar 13, 2009·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Irina S BarequetMordechai Rosner
May 15, 2010·Current Eye Research·Charles L BalzliRichard J O'Callaghan
May 8, 2016·Progress in Retinal and Eye Research·Roger A AstleyMichelle C Callegan

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.